Medical experts feel that the world is behind in time in crossing the bridge on EBOLA
EBOLA- the life threatening virus was first discovered in the year 1976 when it first broke out in the western Africa region. It happened in a small village of Yambuku where almost 5% of the population was working at the same factory. This symptom of wild spread of the virus indicated that the illness was an epidemic. It had a fatal rate of 90% even then which is quite similar to the present day situation. The world today is yet again facing the same misery of loss of lives due to the deadly virus. Pharma companies from across the globe are working round the clock to invent a reliable vaccine for curing the disease but not much has been successful.
However, the latest good news is that after a series of tests and experiments the potential drugs produced are entering the large scale trials in the worst hit regions of Western Africa. This according to the medicine experts can be called as the most important milestone in the history of discovery of cures for any kind of an epidemic. According to a medical journal source- the US study on Ebola virus vaccine has an experiment on 20 healthy people who have no risk of getting infected with the virus; they found that the vaccine developed by joint efforts of GlaxoSmithKline (GSK) and the US National Institute of Allergy and Infectious Diseases (NAID). Sources add that the trials are already to kick-start and will do by mid-January in Sierra-Leona and Liberia where the risk of the virus is still looming.
Institute investing efforts and capital in the activity said that finding vaccine to the virus alone is not the challenge; it is finding a vaccine which is clear- that is it does not raise any other side-effect. In the course of the discovery there are some drugs which are somewhat affective against Ebola but they give rise to other fevers which are unknown and these sorts of side-effects is making the task even tougher for the medicine companies.
So far, there have been more a dozen medicines formulated which were expected to work against the solemn virus but a clear winner is yet to emerge. These drugs can be segmented into 4 categories of curing by now as further developments are soon expected. Drugs are addressed into four kinds which are drugs for targeting the virus before it enters the system or the cells, drugs for blocking the process of virus reproduction (which happens at an unbelievably quick speed), the third segment of drugs are the ones which prevents the virus and infection to exit the system (this prevents the wild spread) and the last set of drugs are the ones that strengthens human cells against the virus.